HilleVax, Inc. (NASDAQ:HLVX) Receives Average Recommendation of “Hold” from Analysts

HilleVax, Inc. (NASDAQ:HLVX) has earned a consensus recommendation of “Hold” from the six analysts that are currently covering the stock, MarketBeat reports. Six research analysts have rated the stock with a hold rating. The average twelve-month price objective among brokers that have covered the stock in the last year is $9.20.

Several brokerages have commented on HLVX. Leerink Partners downgraded HilleVax from an “outperform” rating to a “market perform” rating and lowered their price target for the company from $28.00 to $2.00 in a report on Tuesday, July 9th. Guggenheim lowered shares of HilleVax from a “buy” rating to a “neutral” rating in a research note on Monday, July 8th. JPMorgan Chase & Co. reissued a “neutral” rating and set a $5.00 target price (down previously from $24.00) on shares of HilleVax in a research report on Monday, July 8th. HC Wainwright reaffirmed a “neutral” rating and issued a $2.00 price target on shares of HilleVax in a research report on Monday, August 12th. Finally, Leerink Partnrs cut HilleVax from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, July 9th.

Institutional Trading of HilleVax

Hedge funds and other institutional investors have recently bought and sold shares of the stock. EntryPoint Capital LLC acquired a new position in shares of HilleVax during the first quarter valued at about $80,000. Rhumbline Advisers raised its holdings in HilleVax by 27.0% in the 2nd quarter. Rhumbline Advisers now owns 42,658 shares of the company’s stock valued at $617,000 after acquiring an additional 9,073 shares in the last quarter. Fred Alger Management LLC lifted its position in shares of HilleVax by 9.7% in the 2nd quarter. Fred Alger Management LLC now owns 136,166 shares of the company’s stock worth $1,969,000 after acquiring an additional 12,044 shares during the period. Tidal Investments LLC acquired a new position in shares of HilleVax in the 1st quarter valued at $207,000. Finally, Maven Securities LTD bought a new position in shares of HilleVax during the 2nd quarter worth about $217,000. 86.42% of the stock is currently owned by institutional investors and hedge funds.

HilleVax Trading Up 2.7 %

HLVX stock opened at $1.87 on Friday. The firm has a market cap of $92.98 million, a PE ratio of -0.57 and a beta of 0.80. HilleVax has a 1 year low of $1.55 and a 1 year high of $20.22. The company has a fifty day simple moving average of $1.80 and a 200 day simple moving average of $7.60.

HilleVax (NASDAQ:HLVX) last released its quarterly earnings results on Thursday, August 8th. The company reported ($0.83) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.73) by ($0.10). As a group, analysts forecast that HilleVax will post -2.47 EPS for the current fiscal year.

HilleVax Company Profile

HilleVax, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. It develops HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. The company was formerly known as MokshaCo, Inc and changed its name to HilleVax, Inc in February 2021.